Annual EBITDA
-$25.06 M
-$10.19 M-68.51%
31 December 2023
Summary:
Context Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$25.06 million, with the most recent change of -$10.19 million (-68.51%) on 31 December 2023. During the last 3 years, it has fallen by -$32.37 million (-443.03%). CNTX annual EBITDA is now -443.03% below its all-time high of $7.31 million, reached on 31 December 2020.CNTX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$18.70 M
-$15.61 M-505.92%
01 September 2024
Summary:
Context Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$18.70 million, with the most recent change of -$15.61 million (-505.92%) on 01 September 2024. Over the past year, it has dropped by -$12.52 million (-202.69%). CNTX quarterly EBITDA is now -344.92% below its all-time high of $7.63 million, reached on 30 June 2020.CNTX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$32.54 M
-$12.52 M-62.56%
01 September 2024
Summary:
Context Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$32.54 million, with the most recent change of -$12.52 million (-62.56%) on 01 September 2024. Over the past year, it has dropped by -$10.53 million (-47.83%). CNTX TTM EBITDA is now -470.69% below its all-time high of $8.78 million, reached on 30 June 2020.CNTX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CNTX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -68.5% | -202.7% | -47.8% |
| 3 y3 years | -443.0% | -1092.4% | -546.0% |
| 5 y5 years | - | - | - |
CNTX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -443.0% | at low | -1092.4% | at low | -546.0% | at low |
| 5 y | 5 years | -443.0% | at low | -344.9% | at low | -470.7% | at low |
| alltime | all time | -443.0% | at low | -344.9% | at low | -470.7% | at low |
Context Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$18.70 M(+505.9%) | -$32.54 M(+62.6%) |
| June 2024 | - | -$3.09 M(-19.2%) | -$20.01 M(-9.9%) |
| Mar 2024 | - | -$3.82 M(-44.9%) | -$22.22 M(-11.3%) |
| Dec 2023 | -$25.06 M(+68.5%) | -$6.93 M(+12.2%) | -$25.06 M(+13.9%) |
| Sept 2023 | - | -$6.18 M(+16.8%) | -$22.01 M(+10.7%) |
| June 2023 | - | -$5.29 M(-20.6%) | -$19.88 M(+9.9%) |
| Mar 2023 | - | -$6.66 M(+71.8%) | -$18.09 M(+21.7%) |
| Dec 2022 | -$14.87 M | -$3.88 M(-4.1%) | -$14.87 M(-12.7%) |
| Sept 2022 | - | -$4.04 M(+15.4%) | -$17.04 M(+17.0%) |
| June 2022 | - | -$3.50 M(+1.8%) | -$14.56 M(+12.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$3.44 M(-43.1%) | -$13.00 M(+25.0%) |
| Dec 2021 | -$10.39 M(-242.3%) | -$6.05 M(+285.6%) | -$10.39 M(+106.3%) |
| Sept 2021 | - | -$1.57 M(-19.1%) | -$5.04 M(+18.5%) |
| June 2021 | - | -$1.94 M(+130.6%) | -$4.25 M(-179.8%) |
| Mar 2021 | - | -$840.30 K(+21.7%) | $5.32 M(-27.1%) |
| Dec 2020 | $7.31 M(-238.3%) | -$690.30 K(-11.6%) | $7.31 M(-8.6%) |
| Sept 2020 | - | -$781.00 K(-110.2%) | $8.00 M(-8.9%) |
| June 2020 | - | $7.63 M(+568.2%) | $8.78 M(+668.2%) |
| Mar 2020 | - | $1.14 M | $1.14 M |
| Dec 2019 | -$5.28 M | - | - |
FAQ
- What is Context Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Context Therapeutics?
- What is Context Therapeutics annual EBITDA year-on-year change?
- What is Context Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Context Therapeutics?
- What is Context Therapeutics quarterly EBITDA year-on-year change?
- What is Context Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Context Therapeutics?
- What is Context Therapeutics TTM EBITDA year-on-year change?
What is Context Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of CNTX is -$25.06 M
What is the all time high annual EBITDA for Context Therapeutics?
Context Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is $7.31 M
What is Context Therapeutics annual EBITDA year-on-year change?
Over the past year, CNTX annual earnings before interest, taxes, depreciation & amortization has changed by -$10.19 M (-68.51%)
What is Context Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of CNTX is -$18.70 M
What is the all time high quarterly EBITDA for Context Therapeutics?
Context Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $7.63 M
What is Context Therapeutics quarterly EBITDA year-on-year change?
Over the past year, CNTX quarterly earnings before interest, taxes, depreciation & amortization has changed by -$12.52 M (-202.69%)
What is Context Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of CNTX is -$32.54 M
What is the all time high TTM EBITDA for Context Therapeutics?
Context Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is $8.78 M
What is Context Therapeutics TTM EBITDA year-on-year change?
Over the past year, CNTX TTM earnings before interest, taxes, depreciation & amortization has changed by -$10.53 M (-47.83%)